STOCK TITAN

Artivion to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Artivion, Inc. (AORT) to participate in Oppenheimer Healthcare Conference. Virtual fireside chat on aortic disease scheduled for March 13, 2023.
Positive
  • None.
Negative
  • None.

ATLANTA, March 6, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming Oppenheimer 34th Annual Healthcare MedTech & Services Conference. The Company's virtual fireside chat is scheduled to begin at 10:40 a.m. ET on March 13, 2023.

A live webcast of the virtual fireside chat will be accessible through Artivion's website, www.artivion.com, on the Investors page. An archived copy of the webcast will be available for 90 days on the same website. 

About Artivion, Inc.
Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.Artivion.com.

Contacts:

Artivion

Gilmartin Group LLC

Lance A. Berry

Brian Johnston / Laine Morgan

Executive Vice President &

Phone: 332-895-3222

Chief Financial Officer

investors@artivion.com 

Phone: 770-419-3355


 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/artivion-to-participate-in-the-oppenheimer-34th-annual-healthcare-medtech--services-conference-302081998.html

SOURCE Artivion, Inc.

Artivion, Inc. will participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference on March 13, 2023.

Artivion, Inc. is a leading cardiac and vascular surgery company focused on aortic disease.

Investors can access the live webcast of Artivion, Inc.'s virtual fireside chat on the Investors page of the company's website, www.artivion.com.

The archived copy of the webcast will be available for 90 days on Artivion, Inc.'s website, www.artivion.com.
Artivion Inc

NYSE:AORT

AORT Rankings

AORT Latest News

AORT Stock Data

Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Kennesaw

About AORT

cryolife, headquartered in georgia, is a leader in the processing and distribution of human tissues for use in cardiac and vascular surgeries. cryolife using its proprietary synergraft® technology processes the cryovalve® sg pulmonary heart valve and cryopatch® sg pulmonary cardiac patch. cryolife’s bioglue® surgical adhesive is approved in the u.s. for use as an adjunct to sutures and staples to help control bleeding, ce marked in the european community, approved in canada and australia for use in soft tissue repair, and in japan for use in the repair of aortic dissections. cryolife’s cardiogenesis specializes in the treatment of severe angina using a laser console system and fiber-optic handpieces to perform a surgical procedure known as transmyocardial revascularization (tmr). cryolife markets the hero® graft, which provides vascular access for hemodialysis patients. cryolife distributes perclot®, an absorbable powdered hemostat, in international markets. cryolife’s biofoam® surgica